标题
Enriching cancer pharmacology with drugs of marine origin
作者
关键词
-
出版物
BRITISH JOURNAL OF PHARMACOLOGY
Volume 177, Issue 1, Pages 3-27
出版商
Wiley
发表日期
2019-10-17
DOI
10.1111/bph.14876
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer
- (2018) KOICHI SAKAGUCHI et al. ANTICANCER RESEARCH
- Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells
- (2018) Carlos M. Galmarini et al. BMC CANCER
- Marine natural products
- (2018) John W. Blunt et al. NATURAL PRODUCT REPORTS
- OUP accepted manuscript
- (2018) NEURO-ONCOLOGY
- A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)
- (2018) Eric S. Schafer et al. PEDIATRIC BLOOD & CANCER
- Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition
- (2018) Takaaki Oba et al. Oncotarget
- Antitumor Potential of Marine Natural Products: A Mechanistic Investigation
- (2018) Liping Hu et al. Anti-Cancer Agents in Medicinal Chemistry
- Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study.
- (2018) Jose Manuel Trigo Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group
- (2018) Giovanni Grignani et al. LANCET ONCOLOGY
- Marine Natural Products in Medicinal Chemistry
- (2018) Carlos Jiménez ACS Medicinal Chemistry Letters
- ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line
- (2018) Anna F Farago et al. Future Oncology
- Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer
- (2018) Eriko Yokoi et al. INVESTIGATIONAL NEW DRUGS
- First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
- (2018) Elena Elez et al. INVESTIGATIONAL NEW DRUGS
- Clogging the Ubiquitin-Proteasome Machinery with Marine Natural Products: Last Decade Update
- (2018) Gerardo Della Sala et al. Marine Drugs
- The antitumor drugs trabectedin and lurbinectedin induce transcription-dependent replication stress and genome instability
- (2018) Emanuela Tumini et al. MOLECULAR CANCER RESEARCH
- Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine
- (2017) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?
- (2017) Luca Pompili et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates
- (2017) David Newman et al. Marine Drugs
- The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
- (2017) Simon D Harding et al. NUCLEIC ACIDS RESEARCH
- Efficacy of eribulin in breast cancer: a short report on the emerging new data
- (2017) Gelareh Eslamian et al. OncoTargets and Therapy
- Plitidepsin: design, development, and potential place in therapy
- (2017) Sara Alonso-Álvarez et al. Drug Design Development and Therapy
- Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models
- (2017) Lucia Martinez-Cruzado et al. NEOPLASIA
- Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives
- (2016) Erlinda M. Gordon et al. ADVANCES IN THERAPY
- Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1
- (2016) P. G. Richardson et al. BLOOD
- Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus
- (2016) Matt L. Harlow et al. CANCER RESEARCH
- Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?
- (2016) Qian Zhang et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results
- (2016) S. J. Harrison et al. CLINICAL CANCER RESEARCH
- One size does not fit all: Challenging some dogmas and taboos in drug discovery
- (2016) Christina LL Chai et al. Future Medicinal Chemistry
- Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma†
- (2016) Akira Kawai et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases
- (2016) Yannis Metaxas et al. LUNG CANCER
- Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
- (2016) G. Santamaria Nunez et al. MOLECULAR CANCER THERAPEUTICS
- Counting on natural products for drug design
- (2016) Tiago Rodrigues et al. Nature Chemistry
- Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary
- (2016) Ryoko Takahashi et al. PLoS One
- Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin
- (2016) Alejandro Losada et al. Scientific Reports
- Thiarabine, 1-(4-Thio-β-D-arabinofuranosyl)cytosine. A Deoxycytidine Analog With Excellent Anticancer Activity
- (2015) W.B. Parker et al. CURRENT MEDICINAL CHEMISTRY
- Antibody-drug conjugates: Intellectual property considerations
- (2015) Ulrich Storz mAbs
- Can Some Marine-Derived Fungal Metabolites Become Actual Anticancer Agents?
- (2015) Nelson Gomes et al. Marine Drugs
- Up-regulation of eEF1A2 promotes proliferation and inhibits apoptosis in prostate cancer
- (2014) Yue Sun et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors
- (2014) Marta Martínez-Díez et al. BIOCHEMICAL PHARMACOLOGY
- Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
- (2014) Kristi McIntyre et al. BREAST CANCER RESEARCH AND TREATMENT
- Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states
- (2014) T Yoshida et al. BRITISH JOURNAL OF CANCER
- Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
- (2014) Yasuhiro Funahashi et al. CANCER SCIENCE
- Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
- (2014) Carlos Galmarini et al. Marine Drugs
- Access to and use of marine genetic resources: understanding the legal framework
- (2014) Laura E. Lallier et al. NATURAL PRODUCT REPORTS
- New Interfacial Microtubule Inhibitors of Marine Origin, PM050489/PM060184, with Potent Antitumor Activity and a Distinct Mechanism
- (2013) Benet Pera et al. ACS Chemical Biology
- From old alkylating agents to new minor groove binders
- (2013) Stéphane Puyo et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Trabectedin mechanism of action: what’s new?
- (2013) Maurizio D’Incalci Future Oncology
- Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
- (2013) V. Ribrag et al. HAEMATOLOGICA
- Comparison ofin vitroandin vivobiological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)
- (2013) Michela Romano et al. INTERNATIONAL JOURNAL OF CANCER
- Isolation and First Total Synthesis of PM050489 and PM060184, Two New Marine Anticancer Compounds
- (2013) María Jesús Martín et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
- (2013) Lars Petter Jordheim et al. NATURE REVIEWS DRUG DISCOVERY
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Brentuximab vedotin
- (2012) Anas Younes et al. NATURE REVIEWS DRUG DISCOVERY
- A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
- (2011) K. Aogi et al. ANNALS OF ONCOLOGY
- A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells
- (2011) A. V. Singh et al. BLOOD
- XPF-Dependent DNA Breaks and RNA Polymerase II Arrest Induced by Antitumor DNA Interstrand Crosslinking-Mimetic Alkaloids
- (2011) Sascha Feuerhahn et al. CHEMISTRY & BIOLOGY
- Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
- (2011) B. C. Potts et al. CURRENT CANCER DRUG TARGETS
- CD30-targeted antibody therapy
- (2011) Anas Younes CURRENT OPINION IN ONCOLOGY
- A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study
- (2011) Bradley J. Monk et al. GYNECOLOGIC ONCOLOGY
- Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
- (2011) Michael Millward et al. INVESTIGATIONAL NEW DRUGS
- Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
- (2011) Patrick Schöffski et al. LANCET ONCOLOGY
- Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
- (2011) D. G. Soares et al. MOLECULAR CANCER THERAPEUTICS
- PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity
- (2010) JFM Leal et al. BRITISH JOURNAL OF PHARMACOLOGY
- Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma
- (2010) M. V. Mateos et al. CLINICAL CANCER RESEARCH
- Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas
- (2010) M. M. Mita et al. CLINICAL CANCER RESEARCH
- Marine natural products as sources of novel scaffolds: achievement and concern
- (2010) De-Xin Kong et al. DRUG DISCOVERY TODAY
- The pharmaceutical value of marine biodiversity for anti-cancer drug discovery
- (2010) Patrick M. Erwin et al. ECOLOGICAL ECONOMICS
- eEF1A: Thinking Outside the Ribosome
- (2010) Maria K. Mateyak et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
- (2010) Javier Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- A Review of Trabectedin (ET-743): A Unique Mechanism of Action
- (2010) Maurizio D'Incalci et al. MOLECULAR CANCER THERAPEUTICS
- What lies underneath: Conserving the oceans' genetic resources
- (2010) J. M. Arrieta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
- (2009) Laurent Ducry et al. BIOCONJUGATE CHEMISTRY
- Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells
- (2009) C. P. Miller et al. BLOOD
- Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma
- (2009) D. Chauhan et al. BLOOD
- A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
- (2009) S. Goel et al. CLINICAL CANCER RESEARCH
- Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
- (2009) A. R. Tan et al. CLINICAL CANCER RESEARCH
- Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia?
- (2009) Hong-Fang Ji et al. EMBO REPORTS
- Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2009) Linda T. Vahdat et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
- (2009) C. Forni et al. MOLECULAR CANCER THERAPEUTICS
- Defined salt formulations for the growth of Salinispora tropica strain NPS21184 and the production of salinosporamide A (NPI-0052) and related analogs
- (2008) Ginger Tsueng et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Population pharmacokinetics meta-analysis of plitidepsin (Aplidin®) in cancer subjects
- (2008) Ricardo Nalda-Molina et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Xenohormesis: Sensing the Chemical Cues of Other Species
- (2008) Konrad T. Howitz et al. CELL
- Von Hippel-Lindau-Coupled and Transcription-Coupled Nucleotide Excision Repair-Dependent Degradation of RNA Polymerase II in Response to Trabectedin
- (2008) G. J. Aune et al. CLINICAL CANCER RESEARCH
- Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
- (2008) T. Okouneva et al. MOLECULAR CANCER THERAPEUTICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started